Iris Pauporté

19.6k total citations
13 papers, 339 citations indexed

About

Iris Pauporté is a scholar working on Oncology, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Iris Pauporté has authored 13 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Economics and Econometrics and 4 papers in Cancer Research. Recurrent topics in Iris Pauporté's work include HER2/EGFR in Cancer Research (7 papers), Peptidase Inhibition and Analysis (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Iris Pauporté is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Peptidase Inhibition and Analysis (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Iris Pauporté collaborates with scholars based in France, United States and Switzerland. Iris Pauporté's co-authors include Marc Espié, Gilles Romieu, P. Fumoleau, Jean‐Yves Pierga, Alain Lortholary, Andrew Kramar, Pierre Kerbrat, David Khayat, Thomas Bachelot and Stéphanie Catala and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Iris Pauporté

12 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iris Pauporté France 6 296 144 123 66 46 13 339
Veerle Van Dooren Belgium 5 293 1.0× 165 1.1× 121 1.0× 109 1.7× 71 1.5× 8 401
C Vogel United States 6 302 1.0× 67 0.5× 128 1.0× 21 0.3× 54 1.2× 8 332
Nathalie Quénel-Tueux France 7 183 0.6× 58 0.4× 72 0.6× 9 0.1× 65 1.4× 14 295
Rita Ceccherini Italy 8 182 0.6× 21 0.1× 166 1.3× 37 0.6× 44 1.0× 15 272
Ivica Ratoša Slovenia 8 93 0.3× 48 0.3× 88 0.7× 23 0.3× 84 1.8× 29 208
Kristina Lübbe Germany 8 142 0.5× 25 0.2× 148 1.2× 24 0.4× 75 1.6× 25 277
H Robertshaw United Kingdom 5 202 0.7× 23 0.2× 159 1.3× 17 0.3× 54 1.2× 5 310
Tanja Badovinac Črnjević Switzerland 9 238 0.8× 119 0.8× 64 0.5× 4 0.1× 106 2.3× 16 326
Guzel Mukhametshina Russia 7 143 0.5× 46 0.3× 12 0.1× 27 0.4× 91 2.0× 15 190
R Joseph Bender United States 8 240 0.8× 15 0.1× 226 1.8× 15 0.2× 105 2.3× 15 358

Countries citing papers authored by Iris Pauporté

Since Specialization
Citations

This map shows the geographic impact of Iris Pauporté's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Pauporté with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Pauporté more than expected).

Fields of papers citing papers by Iris Pauporté

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Pauporté. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Pauporté. The network helps show where Iris Pauporté may publish in the future.

Co-authorship network of co-authors of Iris Pauporté

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Pauporté. A scholar is included among the top collaborators of Iris Pauporté based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Pauporté. Iris Pauporté is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Paget‐Bailly, Sophie, P. Fumoleau, Gilles Romieu, et al.. (2018). Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab. The Breast. 41. 1–7. 8 indexed citations
2.
Lefeuvre, D., Christine Le Bihan-Benjamin, Iris Pauporté, Jacques Médioni, & Philippe‐Jean Bousquet. (2017). French Medico-Administrative Data to Identify the Care Pathways of Women With Breast Cancer. Clinical Breast Cancer. 17(4). e191–e197. 5 indexed citations
3.
4.
Ferrari, Anthony, Anne-Sophie Sertier, Anne Vincent‐Salomon, et al.. (2016). A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers. Molecular & Cellular Oncology. 3(6). e1232186–e1232186. 5 indexed citations
5.
Pivot, Xavier, Thomas Suter, J.-M. Nabholtz, et al.. (2015). Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. European Journal of Cancer. 51(13). 1660–1666. 49 indexed citations
6.
Kramar, A., Thomas Bachelot, Jean‐Yves Pierga, et al.. (2014). Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. Annals of Oncology. 25(8). 1563–1570. 18 indexed citations
7.
8.
Pivot, X., Gilles Romieu, Marc Debled, et al.. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The Lancet Oncology. 14(8). 741–748. 211 indexed citations
9.
Pauporté, Iris, et al.. (2013). A national survey on patients’ enrollment rate in oncology clinical trials: The French experience.. Journal of Clinical Oncology. 31(15_suppl). e17567–e17567. 1 indexed citations
10.
Pivot, Xavier, Gilles Romieu, Hervé Bonnefoi, et al.. (2012). Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer. Annals of Oncology. 23. ixe2–ixe2. 13 indexed citations
11.
Pivot, Xavier, Gilles Romieu, Hervé Bonnefoi, et al.. (2012). Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Research. 72(24_Supplement). S5–3. 24 indexed citations
12.
13.
Pauporté, Iris, et al.. (2008). How to improve patients and investigators’ information on clinical trials: The example of French registry for clinical trials in oncology. Journal of Clinical Oncology. 26(15_suppl). 17555–17555. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Veerle Van Dooren Breakdown of academic impact, for papers by C Vogel Breakdown of academic impact, for papers by Nathalie Quénel-Tueux Breakdown of academic impact, for papers by Rita Ceccherini Breakdown of academic impact, for papers by Ivica Ratoša Breakdown of academic impact, for papers by Kristina Lübbe Breakdown of academic impact, for papers by H Robertshaw Breakdown of academic impact, for papers by Tanja Badovinac Črnjević Breakdown of academic impact, for papers by Guzel Mukhametshina Breakdown of academic impact, for papers by R Joseph Bender
Rankless by CCL
2026